The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE
Open accessAbstract
Multiple sclerosis is an inflammatory disease of the central nervous system that begins as a relapsing-remitting disease (RRMS) and is followed by a progressive phase (SPMS). The progressive phase causes the greatest disability and has no effective therapy, but the processes that drive SPMS are mostly unknown. Here we found higher serum concentrations of 15α-hydroxicholestene (15-HC) in patients with SPMS and in mice with secondary progressive experimental autoimmune encephalomyelitis (EAE) but not in patients with RRMS. In mice, 15-HC activated microglia, macrophages and astrocytes through a pathway involving Toll-like receptor 2 (TLR2) and poly(ADP-ribose) polymerase 1 (PARP-1). PARP-1 activity was higher in monocytes of patients with SPMS, and PARP-1 inhibition suppressed the progression of EAE. Thus, the TLR2–PARP-1 pathway is a potential new therapeutic target in SPMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“Both acute and chronic CNS inflammation and demyelination result in axonal damag”
BackgroundMultiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985 · cited 1×
“1775" language="eng" relation="no"> Multiple sclerosis is the leading cause of neurological disability in young adult”
BackgroundCohen-Armon, M., Visochek, L., Rozensal, D., Kalal, A., Geistrikh, I., Klein, R., Bendetz-Nezer, S., Yao, Z., & Seger, R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.012 · Cited by 329
Diestel, A., Aktas, O., Hackel, D., Häke, I., Meier, S., Raine, C. S., Nitsch, R., Zipp, F., & Ullrich, O. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030975 · Cited by 155 · cited 1×
“It has been shown that 7-ketocholesterol (7-KC), an oxidized derivative of cholesterol that is not a 15-oxysterol, activates microglia by a mechanism dependent on the nuclear enzyme PARP-1 (poly(ADP-ribose) polymerase 1) that results in neuronal damage in vitro”
Background
Cited by
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 836
Function and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Self-citationToll-like receptor signaling in neural plasticity and disease
Okun, E., Griffioen, K. J., & Mattson, M. P. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.02.005 · Cited by 510
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation
Mayo, L., Trauger, S. A., Blain, M., Nadeau, M., Patel, B., Alvarez, J. I., Mascanfroni, I. D., Yeste, A., Kivisäkk, P., Kallas, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3681 · Cited by 472
Self-citationMetabolic checkpoints in activated T cells
Wang, R., & Green, D. R. (2012) · Nature Immunology · doi:10.1038/ni.2386 · Cited by 464
TLR-dependent T cell activation in autoimmunity
Mills, K. H. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3095 · Cited by 443
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses
Farez, M. F., Mascanfroni, I. D., Méndez-Huergo, S. P., Yeste, A., Murugaiyan, G., Garo, L. P., Balbuena Aguirre, M. E., Patel, B., Ysrraelit, M. C., Zhu, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.025 · Cited by 318
Reynolds, J. M., Pappu, B. P., Peng, J., Martinez, G. J., Zhang, Y., Chung, Y., Ma, L., Yang, X. O., Nurieva, R. I., Tian, Q., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.010 · Cited by 299
Pathways of cholesterol oxidation via non-enzymatic mechanisms
Iuliano, L. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.06.006 · Cited by 263
The role of PARP1 in neurodegenerative diseases and aging
Mao, K., & Zhang, G. (2022) · The FEBS Journal · doi:10.1111/febs.15716 · Cited by 172
Crowley, T., Cryan, J. F., Downer, E. J., & O’Leary, O. F. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.02.001 · Cited by 150
Role of Sphingolipid Metabolism in Neurodegeneration
Alaamery, M., Albesher, N., Aljawini, N., Alsuwailm, M., Massadeh, S., Wheeler, M. A., Chao, C., & Quintana, F. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15044 · Cited by 129
Self-citationDulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Keene, C. D., Cudaback, E., Li, X., Montine, K. S., & Montine, T. J. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.08.002 · Cited by 103
Van San, E., Debruyne, A. C., Veeckmans, G., Tyurina, Y. Y., Tyurin, V. A., Zheng, H., Choi, S. M., Augustyns, K., van Loo, G., Michalke, B., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01195-0 · Cited by 103
“apoptosis [40], necroptosis [7], parthanatos [41], pyroptosis [42] and netosis [43].”
Calì, C., Cantando, I., Veloz Castillo, M. F., Gonzalez, L., & Bezzi, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168922 · Cited by 66
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity
Brady, P. N., Goel, A., & Johnson, M. A. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-18 · Cited by 58
Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis
Plastini, M. J., Desu, H. L., & Brambilla, R. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00269 · Cited by 48
Cavone, L., Aldinucci, A., Ballerini, C., Biagioli, T., Moroni, F., & Chiarugi, A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511399113 · Cited by 48
Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Maggiore, A., Casale, A. M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagné, J.-P., Poirier, G. G., d’Erme, M., & Piacentini, L. (2022) · Cells · doi:10.3390/cells11081284 · Cited by 40
Doss, P. M. I. A., Umair, M., Baillargeon, J., Fazazi, R., Fudge, N., Akbar, I., Yeola, A. P., Williams, J. B., Leclercq, M., Joly-Beauparlant, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108833 · Cited by 39
Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain
Dang, P. T., Bui, Q., D’Souza, C. S., & Orian, J. M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_378 · Cited by 35
Experimental autoimmune encephalomyelitis (EAE) IN C57Bl/6 mice is not associated with astrogliosis
Pham, H., Doerrbecker, J., Ramp, A. A., D'Souza, C. S., Gorasia, D. G., Purcell, A. W., Ayers, M. M., & Orian, J. M. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.10.006 · Cited by 27
Transcription Blockage by DNA Damage in Nucleotide Excision Repair-Related Neurological Dysfunctions
Kajitani, G. S., Nascimento, L. L. D. S., Neves, M. R. D. C., Leandro, G. D. S., Garcia, C. C. M., & Menck, C. F. M. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.10.009 · Cited by 22
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
Baker, D., Nutma, E., O'Shea, H., Cooke, A., Orian, J. M., & Amor, S. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.792 · Cited by 21
“22,36 Glial cell inflammation is thought to be part of the substrate for slow progressive nerve loss in MS. 11 However, the loss of axons and myelin, accumulation of microglial activation and gliosis reported in progressive EAE models, 24–31 is not qualitatively different from that found following the accumulation of d…”
InfluentialMyelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner
Fazazi, M. R., Doss, P. M. I. A., Pereira, R., Fudge, N., Regmi, A., Joly-Beauparlant, C., Akbar, I., Yeola, A. P., Mailhot, B., Baillargeon, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49259-0 · Cited by 21
Buonvicino, D., Ranieri, G., Pratesi, S., Guasti, D., & Chiarugi, A. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113065 · Cited by 18
Buonvicino, D., Ranieri, G., Pratesi, S., Gerace, E., Muzzi, M., Guasti, D., Tofani, L., & Chiarugi, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15058 · Cited by 15
Metadata
- Authors
- Farez, M. F., Quintana, F. J., Gandhi, R., Izquierdo, G., Lucas, M., & Weiner, H. L.
- Venue
- Nature Immunology
- Published
- 2009-08-16
- Volume
- 10
- Issue
- 9
- Pages
- 958-964
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2061885672
- Cited by
- 193
- References
- 8
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.